SCHEMBL7144885

SCHEMBL7144885

CC(C)NC(=O)CCN1CCCCC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.61
ALDH1A1 P00352 6/20 0.53
POLB P06746 2/20 0.53
L3MBTL1 Q9Y468 1/20 0.52
TP53 P04637 2/20 0.50
KMT2A Q03164 2/20 0.50
MEN1 O00255 1/20 0.50
THRB P10828 1/20 0.48
HTT P42858 1/20 0.48
ALOX15 P16050 1/20 0.48
CHRM5 P08912 1/20 0.47
CHRM3 P20309 1/20 0.47
TERT O14746 4/20 0.47
LMNA P02545 1/20 0.46
CYP1A2 P05177 1/20 0.46
MAPK1 P28482 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
GLA P06280 1/20 0.46
ATM Q13315 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27976690 0.98 MAPT (0.58) MAPTALDH1A1POLBL3MBTL1TP53
SCHEMBL23464919 0.92 MAPT (0.50) MAPTALDH1A1POLBTP53KMT2A
SCHEMBL16311954 0.89 MAPK1 (0.56) MAPTALDH1A1POLBL3MBTL1TP53
SCHEMBL18756520 0.86 MAPT (0.54) MAPTALDH1A1POLBL3MBTL1TP53
SCHEMBL13396798 0.84 SMN1; SMN2 (0.61) ALDH1A1KMT2AMEN1HTTALOX15
SCHEMBL19091005 0.84 SIGMAR1 (0.56) MAPTALDH1A1POLBL3MBTL1TP53
SCHEMBL24530727 0.84 CHRM5 (0.44) MAPTALDH1A1POLBTP53KMT2A
SCHEMBL23553268 0.82 HTT (0.49) MAPTALDH1A1POLBL3MBTL1TP53
SCHEMBL19928655 0.82 SIGMAR1 (0.56) MAPTALDH1A1POLBTP53KMT2A
SCHEMBL5105238 0.82 ALDH1A1 (0.50) MAPTALDH1A1POLBTP53KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11638717-B2 Complex of nucleic acid medicine and multibranched lipid SHIONOGI & CO., LTD. (JP) 2023-05-02 US disclosed
US-11638717-B2 Complex of nucleic acid medicine and multibranched lipid SHIONOGI & CO., LTD. (JP) 2023-05-02 US disclosed
US-20200384010-A1 COMPLEX OF NUCLEIC ACID MEDICINE AND MULTIBRANCHED LIPID SHIONOGI & CO., LTD. (JP) 2020-12-10 US disclosed
US-10696707-B2 Polyene macrolide derivative SHIONOGI & CO., LTD. (JP) 2020-06-30 US disclosed
US-20190135847-A1 POLYENE MACROLIDE DERIVATIVE SHIONOGI & CO., LTD. (JP) 2019-05-09 US disclosed
US-10246478-B2 Polyene macrolide derivative SHIONOGI & CO., LTD. (JP) 2019-04-02 US disclosed
US-20170190729-A1 POLYENE MACROLIDE DERIVATIVE SHIONOGI & CO., LTD. (JP) 2017-07-06 US disclosed
US-20170190729-A1 POLYENE MACROLIDE DERIVATIVE SHIONOGI & CO., LTD. (JP) 2017-07-06 US disclosed
US-9695178-B2 6-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-D]pyrimidine analogs as hedgehog pathway signaling inhibitors and therapeutic applications thereof SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) 2017-07-04 US disclosed
US-9695178-B2 6-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-D]pyrimidine analogs as hedgehog pathway signaling inhibitors and therapeutic applications thereof SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) 2017-07-04 US disclosed
US-20090130077-A1 SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS DECODE GENETICS EHF (IS) 2009-05-21 US disclosed
US-20090130077-A1 SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS DECODE GENETICS EHF (IS) 2009-05-21 US disclosed
US-20090130076-A1 SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS DECODE GENETICS EHF (IS) 2009-05-21 US disclosed
US-20090130076-A1 SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS DECODE GENETICS EHF (IS) 2009-05-21 US disclosed
EP-0672047-B1 ANTIALLERGIC IMIDAZO[1,2-a]THIENO[ 2,3-d]AZEPINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2003-05-02 EP disclosed
EP-0393738-B1 Hydroxyalkylfuranyl derivatives JANSSEN PHARMACEUTICA NV (BE) 1994-11-30 EP disclosed
EP-0282133-B1 1-ALKYL SUBSTITUTED BENZIMIDAZOLE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 1993-07-28 EP disclosed
EP-0151826-B1 4-[(Bicyclic heterocyclyl)-methyl and -hetero]-piperidines JANSSEN PHARMACEUTICA N.V. (BE) 1993-03-31 EP disclosed
EP-0393738-A1 Hydroxyalkylfuranyl derivatives JANSSEN PHARMACEUTICA N.V. (BE) 1990-10-24 EP disclosed
EP-0282133-A2 1-alkyl substituted benzimidazole derivatives JANSSEN PHARMACEUTICA N.V. (BE) 1988-09-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11638717-B2 Complex of nucleic acid medicine and multibranched lipid FABP1, POLRMT, SREBF1 MAPT 4017/4885ALDH1A1 3124/4885POLB 69/4885
US-20170190729-A1 POLYENE MACROLIDE DERIVATIVE ERG28, RPL23, RPL10 MAPT 2901/4885ALDH1A1 4446/4885POLB 801/4885
US-20200384010-A1 COMPLEX OF NUCLEIC ACID MEDICINE AND MULTIBRANCHED LIPID FABP1, POLRMT, SREBF1 MAPT 4017/4885ALDH1A1 3124/4885POLB 69/4885
US-20090130076-A1 SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS PDE3B, PDE4B, PDE4A MAPT 4489/4885ALDH1A1 330/4885POLB 2136/4885
US-10246478-B2 Polyene macrolide derivative ERG28, RPL23, RPL10 MAPT 2901/4885ALDH1A1 4446/4885POLB 801/4885
US-20190135847-A1 POLYENE MACROLIDE DERIVATIVE ERG28, RPL23, RPL10 MAPT 2901/4885ALDH1A1 4446/4885POLB 801/4885
US-20090130077-A1 SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS PDE4B, PDE4A, PDE3B MAPT 3128/4885ALDH1A1 229/4885POLB 3170/4885
US-10696707-B2 Polyene macrolide derivative ERG28, RPL23, RPL10 MAPT 2901/4885ALDH1A1 4446/4885POLB 801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.